Aurobindo Pharma Share Price | Aurobindo Pharma Stock Screener
AUROPHARMA
Pharmaceuticals
Share Price NSE
₹1426.40
▼
-9.50 (-0.66%)
Share Price BSE
₹1430.90
▼
-4.75 (-0.33%)
As of May 29, 2026, the Aurobindo Pharma share price (NSE: AUROPHARMA) is ₹1,426.40 on NSE and ₹1,430.90 on BSE, down 0.66% from the previous close, with shares trading between ₹1,411.00 and ₹1,453.40, and a 52-week range of ₹1,025.00–₹1,546.70.
Check AUROPHARMA price range for the annual price range and momentum.
Use the Aurobindo Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Aurobindo Pharma Market Cap
₹85,000.30 Cr.
AUROPHARMA P/E Ratio (TTM)
24.29
Aurobindo Pharma P/B Ratio
2.25
EPS (TTM)
₹60.34
Dividend Yield
-
Debt to Equity
0.24
AUROPHARMA 52 Week High
₹1546.70
Aurobindo Pharma 52 Week Low
₹1025.00
Operating Margin
19.00%
Profit Margin
10.38%
AUROPHARMA Revenue (TTM)
₹8,869.00
EBITDA
₹1,766.00
Net Income
₹921.00
Total Assets
₹58,502.00
Total Equity
₹37,891.00
Aurobindo Pharma Share Price Chart
Screen Aurobindo Pharma share price with an interactive chart. Analyse AUROPHARMA price trends and volatility across different timeframes.
Aurobindo Pharma Company Profile - Fundamental Screener
Screen Aurobindo Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AUROPHARMA shares.
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
M R Kumar
ISIN
INE406A01037
Website
https://www.aurobindo.com
Aurobindo Pharma Balance Sheet Screener
Screen AUROPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 58,502 | 49,785 | 45,072 | 39,890 | 33,922 | 33,854 | 28,928 | 26,454 | 21,101 | 16,249 |
| Current Assets | 32,709 | 27,163 | 23,772 | 21,460 | 18,123 | 19,824 | 16,413 | 15,332 | 12,178 | 9,206 |
| Fixed Assets | 21,820 | 14,794 | 14,493 | 11,024 | 10,532 | 9,374 | 9,397 | 8,475 | 6,521 | 4,834 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2,580 | 2,456 | 3,022 | 1,544 | 1,192 | 1,260 | 718 | 541 | 753 | 270 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 37,891 | 32,647 | 29,851 | 26,852 | 24,574 | 21,929 | 16,825 | 13,892 | 11,682 | 9,374 |
| Share Capital | 58 | 58 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves & Surplus | 37,833 | 32,595 | 29,784 | 26,781 | 24,517 | 21,871 | 16,766 | 13,832 | 11,622 | 9,313 |
Aurobindo Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Aurobindo Pharma income statement and profit fundamentals.
Analyze AUROPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aurobindo Pharma share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,869 | 8,516 | 7,899 | 8,359 | 8,793 | 7,628 | 7,679 | 7,783 | 8,052 | 6,514 | 6,907 | 7,339 | 7,434 | 5,844 | 6,218 |
| Expenses | 7,103 | 6,622 | 6,265 | 6,608 | 6,938 | 6,042 | 5,949 | 6,230 | 6,401 | 5,477 | 5,772 | 5,846 | 5,753 | 5,002 | 5,303 |
| EBITDA | 1,766 | 1,894 | 1,634 | 1,752 | 1,855 | 1,585 | 1,730 | 1,553 | 1,652 | 1,037 | 1,135 | 1,493 | 1,681 | 842 | 914 |
| Operating Profit % | 19.00% | 21.00% | 20.00% | 20.00% | 19.00% | 19.00% | 20.00% | 19.00% | 19.00% | 14.00% | 15.00% | 18.00% | 21.00% | 14.00% | 14.00% |
| Depreciation | 479 | 444 | 406 | 429 | 465 | 354 | 404 | 382 | 419 | 346 | 327 | 418 | 423 | 254 | 280 |
| Interest | 98 | 115 | 98 | 95 | 93 | 89 | 111 | 113 | 119 | 56 | 57 | 68 | 76 | 9 | 15 |
| Profit Before Tax | 1,291 | 1,335 | 1,207 | 1,276 | 1,339 | 1,230 | 1,324 | 1,208 | 1,200 | 730 | 812 | 1,076 | 1,262 | 594 | 679 |
| Tax | 370 | 432 | 383 | 428 | 429 | 323 | 406 | 391 | 354 | 224 | 242 | 324 | 323 | 18 | 159 |
| Net Profit | 921 | 903 | 824 | 848 | 910 | 907 | 918 | 817 | 846 | 506 | 570 | 752 | 940 | 576 | 520 |
| EPS | 15.86 | 15.56 | 14.20 | 14.61 | 15.67 | 15.51 | 15.69 | 14.00 | 14.56 | 8.64 | 9.74 | 12.83 | 16.04 | 9.84 | 8.88 |
Aurobindo Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AUROPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,925 | 2,435 | 2,387 | 5,017 | 3,329 | 4,381 | 1,651 | 1,955 | 3,279 | 1,420 |
| Investing Activities | -1,866 | -4,242 | -3,971 | -3,211 | 597 | -1,563 | -2,904 | -1,927 | -1,787 | -1,446 |
| Financing Activities | 120 | 800 | 1,814 | -2,969 | -1,365 | -1,947 | 1,919 | 864 | -1,915 | 365 |
| Net Cash Flow | 2,178 | -1,007 | 230 | -1,164 | 2,561 | 871 | 666 | 892 | -424 | 340 |
Aurobindo Pharma Shareholding Pattern Screener
See Aurobindo Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Aurobindo Pharma promoter holding and ownership changes for AUROPHARMA on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.83% | 51.80% | 51.82% |
| FII Holding | 15.24% | 15.33% | 14.37% | 14.21% | 13.94% | 18.02% | 16.73% | 16.59% |
| DII Holding | 25.87% | 26.23% | 26.93% | 27.60% | 27.68% | 23.28% | 24.77% | 25.13% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.74% | 5.47% | 5.67% | 5.25% | 5.36% | 5.52% | 5.47% | 5.33% |
| Other Holding | 1.34% | 1.15% | 1.20% | 1.13% | 1.19% | 1.36% | 1.23% | 1.13% |
| Shareholder Count | 241,298 | 269,323 | 272,208 | 247,662 | 236,859 | 244,575 | 238,622 | 248,488 |
Aurobindo Pharma Share Dividend Screener - Share Yield Analysis
Check Aurobindo Pharma dividend history with payout and yield data.
View Aurobindo Pharma dividend details including ex-dates and amounts for AUROPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹4.50 | 0.39% |
| 2023-March | ₹7.50 | 0.69% |
| 2022-March | ₹9.00 | 1.77% |
| 2021-March | ₹4.00 | 0.60% |
| 2020-March | ₹3.00 | 0.34% |
| 2019-March | ₹2.50 | 0.61% |
| 2018-March | ₹2.50 | 0.32% |
| 2017-March | ₹3.20 | 0.57% |
Aurobindo Pharma Stock Index Membership
See which indices include Aurobindo Pharma stock.
Check AUROPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MIDSEL
BSE INDEX MSL400
NIFTY 200
NIFTY 500
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDCAP 50
NIFTY MIDCAP SELECT (MIDCPNIFTY)
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
NIFTYM150MOMNTM50
Aurobindo Pharma Market Events Screener - Corporate Actions
Get Aurobindo Pharma corporate actions including splits, bonuses, and buybacks.
Check Aurobindo Pharma stock events that may affect AUROPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -0.84% | ||
| 2026-05-21 | 2026-05-21 | Quarterly Result Announcement | NA | 2.13% |
| 2026-04-17 | 2026-04-23 | Buyback | 1475 | -0.03% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 3.52% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 4.74% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 4.00 /share | -0.94% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -1.96% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -1.63% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 3.04% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -4.90% |
| 2024-08-29 | 2024-08-29 | Annual General Meeting | NA | 11.38% |
| 2024-07-30 | 2024-08-05 | Buyback | 1460 | -2.41% |
| 2024-02-20 | 2024-02-20 | Dividend | ₹ 1.50 /share | 3.84% |
| 2023-11-20 | 2023-11-20 | Dividend | ₹ 3.00 /share | 7.58% |
| 2023-02-17 | 2023-02-17 | Dividend | ₹ 3.00 /share | 7.83% |
Aurobindo Pharma Competitors Screener - Peer Comparison
Screen AUROPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,581 | 40.42 | 58,220 | 6.38% | 11,565 | 54.75 |
| Divis Laboratories | 182,828 | 73.73 | 10,560 | 8.73% | 2,520 | 66.48 |
| Torrent Pharmaceuticals | 151,833 | 66.80 | 13,753 | 19.18% | 2,028 | 61.90 |
| Cipla | 113,025 | 29.26 | 27,712 | -2.46% | 3,783 | 61.92 |
| Dr Reddys Laboratories | 109,105 | 26.24 | 33,593 | -0.44% | 3,998 | 52.61 |
| Zydus Life Science | 104,543 | 20.40 | 26,720 | 13.65% | 5,242 | 69.40 |
| Lupin | 104,288 | 19.46 | 27,488 | 19.98% | 5,345 | 47.33 |
| Mankind Pharma | 102,351 | 52.84 | 14,278 | 12.03% | 1,750 | 62.34 |
| Aurobindo Pharma | 85,000 | 24.29 | 33,385 | 3.21% | 3,376 | 52.91 |
| Laurus Labs | 72,530 | 81.46 | 6,813 | 21.03% | 884 | 77.10 |
Aurobindo Pharma Company Announcements - News Screener
Screen AUROPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Classification Of Unit-I Of Eugia Pharma Specialities Limited Shameerpet (Our Wholly Owned Subsidiary) As OAI | - | |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-05-27 | Financial Results For The Year Ended March 31 2026. | - |
| 2026-05-27 | Intimation Of Appointment Of Internal Auditor | - |
| 2026-05-27 | Appointment Of Secretarial Auditor | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-27 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-05-22 | Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-22 | Curateq Biologics Receives CDSCO Marketing Authorisation (Form CT 23) For Bevqolva® (Bevacizumab Biosimilar) | - |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Closure of Buy Back | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-12 | Board Meeting Intimation for Consider And Approve Inter Alia The Standalone & Consolidated Audited Financial Results Of The Company For The Fourth Quarter And Financial Year Ended March 31 2026 | - |
| 2026-05-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-06 | US FDA Classification Of Unit-VII Of Aurobindo Pharma Limited As Voluntary Action Indicated (VAI) | - |
| 2026-05-04 | Intimation Of Resignation Of Dr. Sanjay Chaturvedi CEO Of Apitoria Pharma Private Limited Wholly Owned Subsidiary Of The Company | - |
| 2026-05-01 | Curateq Biologics Secures Health Canada NOC For Bevqolva™ Bevacizumab Biosimilar | - |
| 2026-04-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |